Imugene Ltd (STU:ILA)
€ 0.025 0.002 (8.7%) Market Cap: 234.75 Mil Enterprise Value: 179.08 Mil PE Ratio: 0 PB Ratio: 3.19 GF Score: 0/100

Imugene Ltd Non-Deal Roadshow - Australia Transcript

Mar 22, 2023 / NTS GMT
Leslie Chong
Imugene Limited - CEO & MD

Thank you, everyone, for attending. Some of you have been with the [share stock] since 2013, some of you came in at 2015 when I joined, then on and on, and just recently, so thank you so much. I consider some of you almost friends and family of Imugene because you've been in it maybe even longer than I have.

So 2013, Paul Hopper started this company. I joined roughly in 2015, straight from Genentech to San Francisco to Sydney and Imugene. I worked with Dr. Jakob Dupont. So it's gotten to a point where we're literally bringing in so many talented people. And one of the strict criteria that we have in our organization is that you have to be experts in your field, and Jacob definitely fills that role.

So 2015, I put my head down and developed our HER-Vaxx. Within five years, we were able to finish a Phase 2 study with overall survival data. Now in the field of oncology clinical development, that is lightning speed. You cannot imagine what it takes to take a drug into the clinic and then you hope for amazing data and you get it. So it's been a dream

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot